Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

← catalyst calendar

NCT05516498

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Triple · Screening
Enrollment
205actual
Sites
50
Countries
Australia, Austria, Belgium +12

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

The study was ended earlier than planned due to a sponsor decision.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-10-31actualWhen the study began enrolling
Primary completion2025-05-22actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-07-17actualThe whole study's end, after follow-up
First posted2022-08-25actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-08-15actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Liver Cirrhosis

Interventions

  • Drug: Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)
  • Drug: Part A: zibotentan (dose B) + dapagliflozin
  • Drug: Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)
  • Drug: Part B: placebo (matching zibotentan capsule) + dapagliflozin
  • Drug: Part B: zibotentan (dose A) + dapagliflozin
  • Drug: Part B: zibotentan (dose B) + dapagliflozin
  • Drug: Part B: zibotentan (dose C) + dapagliflozin

Primary outcomes

what the primary-completion date above is the date OF
Part A: Absolute change in HVPG from baseline to Week 6.
measured at Week 6
Part B: Absolute change in HVPG from baseline to Week 6.
measured at Week 6

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed